Indegene already provides operations services to companies among the world’s top 20 biopharmaceutical companies, and has deployed a data quality agent for life sciences on AWS. Our judgment is that the core cost of enterprise AI in its next phase will no longer be merely training larger models; it will be making data scattered across systems and business functions genuinely usable.
What this is
Indegene has connected its data quality agent to the NEXT Unified Data Platform. It can generate data quality rules based on business context, validate those rules, and produce directly runnable SQL and Python code, with final review and approval by both a central team and business users.
Two types of rules need to be distinguished here. Technical rules check whether fields are empty, formats are correct, and identifiers are unique. Business rules assess whether market shares sum to 100% or whether physician prescriptions meet professional and qualification requirements. The latter are often scattered across glossaries, process documents, and employee experience, making them difficult to maintain continuously. The agent’s value lies in converting these implicit business judgments into manageable, executable checks.
Industry view
This approach is worth watching because enterprises often do not lack data; they lack trusted, unified, and continuously updated data. Models, dashboards, and business analytics all depend on underlying data. If the definitions and standards of those inputs are inconsistent, AI will simply produce incorrect conclusions faster. For highly regulated pharmaceutical companies, automatically generated code must be paired with human review and centralized governance to balance efficiency and compliance.
We should also be wary of the misconception that automation automatically means reliability. Rules generated by an agent may omit exception conditions, and improved data quality cannot be measured solely by the number of rules deployed. A project’s ultimate success still depends on whether business definitions are clear, data is traceable, and the organization can sustain the long-term cost of governance. AWS is both the platform provider and the publisher of this case, so Indegene’s claims about efficiency and scalability still require validation through more independent customer results.
Impact on regular people
For enterprise IT: Data governance will shift from a series of discrete projects to continuous operations. IT teams will need to connect rule libraries, business definitions, and model outputs while retaining human approvals and audit trails.
For individual careers: Repetitive work such as data cleansing and preparing validation reports may decline, but business professionals will still need to explain what constitutes trustworthy data. Domain judgment and governance responsibilities will not disappear.
For consumer markets: Decision-making around drug launches, market access, and medical operations may become faster. Consumers may see no immediate difference, but over time, these developments could affect the speed and compliance of pharmaceutical services.